Nevro is a medical device company focused on delivering solutions for patient with pain treatment. Co. has developed and commercialized the Senza® spinal cord stimulation (SCS) system, a neuromodulation platform for the treatment of chronic pain, with the Senza® Omnia platform being an addition to the Senza family of products. Co.'s proprietary, paresthesia-free 10 kHz Therapy, delivered by its Senza system is designed to treat back pain and leg pain. In addition, Co. received approval of unilateral or bilateral pain, associated with painful diabetic neuropathy and expanded labeling in non-surgical refractory back pain. The NVRO YTD return is shown above.
The YTD Return on the NVRO YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether NVRO YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NVRO YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|